Magurol

Doxazosin, the active ingredient in Magurol, is a alpha-1 adrenergic blocker presented as an oral dosage form for oral use. It is used to lower blood pressure and to relieve urinary obstruction caused by an enlarged prostate in adult patients. GNH USA supplies Magurol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Doxazosin acts on the peripheral vascular and prostatic smooth‑muscle alpha‑1 receptors, providing therapeutic benefit in several cardiovascular and urological conditions.

Hypertension: reduces systolic and diastolic blood pressure by vasodilation. Benign prostatic hyperplasia (BPH): eases urinary flow obstruction and lowers residual urine volume. Elevated blood pressure associated with other comorbidities: assists in overall blood‑pressure control when used as part of combination therapy.

Doxazosin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Dizziness or light‑headedness, especially on standing. - Headache. - Fatigue or generalized weakness. - Nasal congestion or rhinorrhea. - Peripheral edema. - Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Priapism (prolonged erection). - Hepatic injury or abnormal liver enzymes. - Anaphylactic or severe allergic reactions. - Worsening heart failure. - Sudden cardiac arrest (very rare).

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension. - Hepatic impairment: use with caution and consider dose adjustment. - Orthostatic hypotension: advise patients to rise slowly from sitting or lying positions. - Concomitant antihypertensives: assess for additive blood‑pressure‑lowering effects. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Doxazosin can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Co‑administration with phosphodiesterase‑5 inhibitors (e.g., sildenafil) may cause profound hypotension. - Use with other potent alpha‑1 blockers (e.g., prazosin) can lead to additive vasodilatory effects.

Moderate Interactions (Monitor Closely):\n- Concurrent diuretics may increase the risk of orthostatic hypotension. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) can blunt antihypertensive response. - CYP3A4 inhibitors (e.g., ketoconazole) may raise plasma levels of doxazosin.